SEC Company Response from AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946) (AXIM) — Aug 2, 2022
AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946)
Date: Aug. 2, 2022 · CIK: 0001514946 · Accession: 0001096906-22-001762
AI Filing Summary & Sentiment
File numbers found in text: 333-266305
Letter
AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E. Suite 114
San Diego, CA 92121
August 2, 2022
VIA EDGAR
Division of Corporation Finance Office of Life Sciences
U.S. Securities & Exchange Commission (the “Commission”)
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Alan Campbell
Re:
AXIM Biotechnologies, Inc.
Registration Statement on Form S-1/A
Filed August 2, 2022
File No. 333-266305
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, AXIM Biotechnologies, Inc. (the “Company”) hereby requests that the effective date for the above-referenced Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-266305) be accelerated so that it will be declared effective at 5:00 PM Eastern Standard Time August 4, 2022, or as soon thereafter as is practicable.
The undersigned, on behalf of the Company, acknowledges the following:
·should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
·the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
·the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States
Sincerely,
AXIM BIOTECHNOLOGIES, INC.
Show Raw Text
CORRESP 1 filename1.htm AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 August 2, 2022 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission (the “Commission”) 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: AXIM Biotechnologies, Inc. Registration Statement on Form S-1/A Filed August 2, 2022 File No. 333-266305 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, AXIM Biotechnologies, Inc. (the “Company”) hereby requests that the effective date for the above-referenced Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-266305) be accelerated so that it will be declared effective at 5:00 PM Eastern Standard Time August 4, 2022, or as soon thereafter as is practicable. The undersigned, on behalf of the Company, acknowledges the following: ·should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; ·the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and ·the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States Sincerely, AXIM BIOTECHNOLOGIES, INC. /s/ John W. Huemoeller II John W. Huemoeller II President